<DOC>
	<DOC>NCT01405131</DOC>
	<brief_summary>A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.</brief_summary>
	<brief_title>A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Healthy male or female subjects between the ages of 21 and 55 years. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight &gt; 45 kg (99 lbs). Any condition possibly affecting drug absorption (eg, gastrectomy). A positive urine drug screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>bioequivalence study</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>suspension</keyword>
	<keyword>tablets</keyword>
</DOC>